Chemical Information
Antiviral agent ID	DrugRepV_4093
Antiviral agent name	Chloroquine
IUPAC Name	4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine
SMILES (canonical)	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
Molecular Formula	C18H26ClN3
Molecular Weight (g/mol)	319.877
InChl	InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)
Common Name	Chloroquine
Synonyms	Chloraquine | Chlorochin | Chloroquina | Chloroquine | Chloroquinium | Chloroquinum | Cloroquina | N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
Structural Information
Clinical Information
Category	Antiparasitic products, Insectisides and Repellents
Primary Indication (Clinical trial phases)	Approved
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Malaria
Primary Indication (Drug target/Mode of Action)	Glypican 3 isoform 2
Secondary Indication	Ebola virus (EBOV) NA Bundibugyo
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	293T/17
Secondary Indication (Mode of viral infection)	Transfection
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Post infection
Secondary Indication (Duration of drug delivery)	24 hours
Secondary Indication (Drug concentration)	3.589 μM
Secondary Indication (Cell based assay)	Inhibition assay
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Long J, Wright E, Molesti E, Temperton N, Barclay W..Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry..Version 2. F1000Res. 2015 Jan 29 [revised 2015 Jan 1];4:30. doi: 10.12688/f1000research.6085.2. eCol PMID:26069727
Comment	In contacts of EBOV cases, chloroquine (CQ) decrease the viral load that establishes in the early days after virus transmission.